Dotted QR code with pixel dinosaur icon
Posted on by Cynthia Johnson

Phase 1/​2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT#: & LinkNCT03785249
NCT QR Code
Available as of:July 15 2024
Contract:Caris
Indication Category:Solid Tumors
Study Sponsor:Mirati Therapeutics
Protocol #:849-001
Title:Phase 1/​2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Highlight Details:***REFERRAL ONLY*** A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Biomarkers:KRAS G12C
Indication:PDAC, Other Solid Tumors
Phase:1/2
Treatment Line:
Study Drug/Test Compound:Adagrasib (MRTX849)
Notes
Recruitment Status:Just In Time
Participating Institution:Salinas Valley Health
Salinas Valley Health Clinical Research Program:Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, research@salinasvalleyhealth.com